Niramai

includes Niramai Thermalytix

0 statements across 0 episodes · 10 bullish · 0 bearish · 3 people on the record · first statement Feb 12, 2020 by Manish Singhal · said 18 times in 3 episodes since 2020 · across every show →

Mentions by year, the whole family

brought up most by Siddhartha Ahluwalia (10), Manish Singhal (2)

tap a year for its mentions
008115220202021episodesmentions
01220202021episodes it came up in
007.5115220202021episodesmentions per episode
2021 14 mentions in 1 episode
2020 4 mentions in 2 episodes 2 per episode

every mention, scene by scene, with the transcript →

Everything said about Niramai, oldest first

Feb 12, 2020 bullish
Disclosure
Singhal: pi Ventures was the first investor in Niramai when others hesitated
“When we did Nirami investment, we were the first investor in, and because it was a very disruptive startup not many people, they were interested, but not coming sort of forward. So, but when we sort of said, okay, we are going to do this, right, then we saw so…”
Manish Singhal Feb 12, 2020 ▶ 24:27 Episode 51 | Manish Singhal, pi Ventures
Feb 18, 2021 bullish
Assertion Not checkable as stated
Every clinician who tested Niramai's screening tool has purchased it
“Anyone who has tested actually sort of gone ahead and bought the solution.”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 41:11 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021 positive
Disclosure
Niramai Measures 400,000 Temperature Points Per Patient with Thermal Sensors
“So like per person, we measure 400,000. That is four lakh temperature points with these high resolution high sensitivity thermal sensors, thermal cameras.”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 26:07 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021 positive
Assertion Supported
Niramai's hospital screening costs 1,500 INR, one-third of a mammogram
“So in a hospital, it's about one third the cost of a mammography machine, mammography tests, sorry, which basically can be around 1500 rupees in India.”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 27:46 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021
Assertion Supported
Manjunath: BMS Hospital became Niramai's reference customer within six months
“Within about six months or so we were able to convince a hospital to provide the solution in, their, you know, as a reference customer BMS hospital gave this as a test in their own hospital.”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 16:30 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021 neutral
Assertion Supported
Dream Incubator Led Niramai's Series A Alongside BEENEXT
“Dream incubator came in as a lead investor. Then we have Bnext and a couple of strategic investors also coming in.”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 33:22 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021 bullish
Assertion Not checkable as stated
Niramai's thermal tech can be applied to detect other cancers
“It's a technology that we have developed and can be used for several other types of cancers because all other types of cancers or many, many Of those also depict a similar thermal signature that we can find too. So not just for cancer as well, this can be used…”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 46:45 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021 positive
Assertion Supported
Niramai's breast cancer screening is deployed across 15 Indian cities
“So now we have it in 15 cities in India established in multiple, like Bangalore, Delhi, Chennai, Mysore, Bhuvaneswar, Dehradun, all of these places, Savopal, all of these places we do have the test available.”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 29:07 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021
Insight
Healthtech startups must validate on real patients, not lab results
“Clinical efficacy of the result is very, very important. We can't say we will do a health tech startup and go with the lab level, you know, result, you know. Trying to show this work on real patients of walking into a hospital and trying to show that your solu…”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 37:40 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021 positive
Assertion Supported
Niramai Has Screened 30,000+ Women Across 70+ Hospitals
“Thankfully we do have 30,000 plus women, you know, who are able to come and stand in front of us and like take the test, you know, it's the trust of the end users and we have 70 plus hospitals who have actually fully convinced their doctors, convinced their ma…”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 31:24 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021 positive
Assertion Supported
Niramai completes ISO 13485 audit and awaits CE mark clearance
“Recently, as I mentioned, we also got an ISO 34 85 clearance, as in, we finished the audit and we're expecting the certificate at any time, and also a CE marking.”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 45:13 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021 positive
Assertion Supported
Niramai was the only Indian startup in CB Insights' 2019 AI 100 list
“Her company, Niramai, is the only Indian company listed in the 2019 cohort of AI hundred startups in the world by global business data intelligence platform, CB Insights.”
Siddhartha Ahluwalia Feb 18, 2021 ▶ 2:32 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021 neutral
Assertion Supported
Niramai pitched 40 to 50 investors to raise $6M Series A
“We raised six million in this CDCA, and we and I actually met multiple investors this time, you know, many, many more investors than we met in seed round you know. 40, 50 investors, right”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 32:36 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Feb 18, 2021 positive
Assertion Supported
Niramai's automated rural triage screening costs just 100 INR per test
“And so, so this, ah, is, this is almost hundred rupees per test, assuming the hardware is covered.”
Dr. Geetha Manjunath Feb 18, 2021 ▶ 28:38 Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 300 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.